Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q2 FY26 results · Jul–Sep 2025
Metropolis Healthcare reported revenue from operations of ₹429.19 crore (up 22.7% from Q2 FY25) and net profit of ₹52.89 crore (up 13.3% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 429.19 | 349.79 | +22.7% | 386.06 | +11.2% |
| Other income | 0.89 | 3.13 | −71.5% | 7.52 | −88.1% |
| Total income | 430.08 | 352.92 | +21.9% | 393.58 | +9.3% |
| Profit before tax | 71.03 | 61.40 | +15.7% | 61.23 | +16.0% |
| Net profit for the period | 52.89 | 46.70 | +13.3% | 45.25 | +16.9% |
| Attributable to shareholders of the company | 52.67 | 46.52 | +13.2% | 45.06 | +16.9% |
| EPS, basic (₹) | 10.17 | 9.08 | +12.1% | 8.70 | +16.9% |
| Net margin (%) | 12.3 | 13.4 | 11.7 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 355.71 | 321.57 | +10.6% | 323.63 | +9.9% |
| Other income | 2.52 | 3.59 | −29.9% | 2.78 | −9.3% |
| Total income | 358.23 | 325.16 | +10.2% | 326.41 | +9.7% |
| Profit before tax | 62.12 | 54.87 | +13.2% | 47.68 | +30.3% |
| Net profit for the period | 46.63 | 42.26 | +10.3% | 35.58 | +31.1% |
| EPS, basic (₹) | 9.00 | 8.24 | +9.2% | 6.87 | +31.0% |
| Net margin (%) | 13.1 | 13.1 | 11.0 |
Consolidated
- Filed with BSE
- 04 Nov 2025, 21:08 IST
- Board meeting
- 04 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2025, 21:08 IST
- Board meeting
- 04 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE